Open Calls for Proposals

Established Investigator Awards support senior investigators with an established record of scientific productivity and accomplishment.  Term: 3 Years  Amount: Up to $125,000 per year for three years (up to $375,000 total)

https://www.curemelanoma.org/research/request-for-proposals/mra-general-rfp

Stage 1: short proposal, Stage 2: Support phase, invited Stage 3: Full proposal
To support multinational, GCP‑compliant early‑phase interventional clinical trials in rare diseases.
Priority areas: paediatric rare diseases; rapidly progressive rare diseases; and rare diseases with no approved therapeutic options or with substantial residual unmet medical need despite existing treatments.
* Each consortium must designate a Clinical Trial Sponsor and a Coordinating Investigator, include at least one funded patient partner (via a PAO or other organised patient group), and secure access to a qualified multinational Clinical Trial Management Organisation (CTMO).
Only multinational trials will be funded (minimum of three independent eligible partner institutions from at least three different eligible countries; PAOs focused primarily on PPIE do not count towards this minimum).
https://erdera.org/call/ctc2026/
Information webinar: 6 July 2026, 15:00–17:00 CEST. More information and registration: https://erdera.org/event/erdera-clinical-trial-call-2026-information-webinar/.

Young Investigator Awards aim to attract early career faculty with original ideas into the field of melanoma, thereby recruiting and supporting the next generation of melanoma research leaders. Awardees will be provided with funding to accomplish innovative and original, preclinical, translational, and/or early clinical research projects. Young Investigators are scientists within the first five years of their first academic faculty appointment. A mentorship commitment from a senior investigator at the applicant’s institution is required. Term: 3 Years Amount: Up to $85,000 per year for three years (up to $255,000 total)

https://www.curemelanoma.org/research/request-for-proposals/mra-general-rfp

Pilot Awards support senior investigators who propose potentially transformative ideas that do not have extensive preliminary data but articulate a clear hypothesis and translational goals. Resources for such “high-risk, high-reward” projects are important to establish proof-ofconcept, which may then leverage additional funding through more traditional avenues.  Term: 2 Years Amount: Up to $50,000 per year for two years (up to $100,000 total)

https://www.curemelanoma.org/research/request-for-proposals/mra-general-rfp

Designed to encourage basic research, technological innovation, and informatics pipeline development that can lead to an understanding of blood cancer disease mechanisms, the development of improved methods for detecting and monitoring cancer progression, and the identification of novel therapeutic targets. This is a dedicated mechanism to encourage established investigators to explore the biology of blood cancer and support proof-of-concept studies that could initiate completely novel approaches to treatment.
Funding: up to $250K per year / $750K total for 3 years
https://bloodcancerunited.org/research/grants/discovery-grant-program-dgp

The Preeclampsia Foundation is seeking Letters of Intent for the Peter Joseph Pappas Research Grants funding program, designed to accelerate preeclampsia research. The ultimate goal of this grant program is to drive research that will eliminate the delivery of pre-term babies as an intervention for severe preeclampsia, HELLP syndrome, and related hypertensive disorders of pregnancy. Named for the infant son of preeclampsia survivor Lauren Pappas and her husband Clement, the program seeks to award multiple two-year grants in 2026 totaling up to $200,000.

https://www.preeclampsia.org/research-funding

The Alzheimer’s Association Research Grant for All (AARGA) program aims to fund early-career investigators who have been in the position of Assistant Professor or the equivalent for no more than seven (7) years. The purpose of this program is to provide newly independent investigators with funding that will allow them to develop preliminary or pilot data, to test procedures and to develop hypotheses. The intent is to support early-career development of newly independent researchers/clinicians that will lay the groundwork for future research grant applications to federal or other funding entities.

Funding: up to $70,000 per year for 3 years

View more details

General Research Grant
Supports basic, translational and clinical research with the goal of advancing therapeutic development in FA.
Funding: up to $125K per year for 1 or 2 years
Postdoctoral Research Award
A mechanism to expand and retain young investigators in the FA biomedical research space. Competitive candidates demonstrate qualities that will enhance FARA’s overall enterprise of understanding fundamentals of disease pathology and developing treatments and a cure for FA.
Funding: up to $100K per year for 1 or 2 years
https://www.curefa.org/research/grant-program/grant-type/#scientist

Funds groundbreaking scientific research that brings us closer to effective treatments and improved care for individuals with Angelman syndrome (AS). The call for research proposals invites scientists and clinicians worldwide to submit innovative studies that align with 2025 ASF Research Roadmap and priorities:

* UBE3A Regulation and Function – rigorous research towards understanding how UBE3A expression is regulated and how UBE3A functions in protein homeostasis and in neuronal function.

* Cutting Edge Therapeutic Strategies – study and development of new therapeutic approaches and the translational

studies required for their advancement to the clinic.

* Clinical Care and Innovation – Enhance the quality of life and well-being of individuals with Angelman Syndrome through comprehensive and personalized clinical care approaches.

* Therapeutic Endpoints and Biomarkers – explore and develop endpoints and biomarkers to improve clinical

trial design and measurement of response beyond physician and caregiver reported measures.  Establish objective measures of treatment response and disease progression to facilitate the evaluation of therapeutic interventions for Angelman Syndrome.

Funding: up to $100,000/year for up to 2 years.

https://angelman.org/call-for-proposals/

Translational Research Award (TRA): Supports mature high-impact translational research that will accelerate innovative ideas into clinical applications, including health care products, technologies and/or practice guidelines.

Funding: up to $1.45M for 2 years

https://cdmrp.health.mil/funding/crrp

https://ebrap.org/eBRAP/public/Program.htm

The PKD Foundation’s principal mission is to support basic, translational, and clinical research that will benefit patients with autosomal dominant and autosomal recessive polycystic kidney disease (ADPKD and ARPKD):

• Basic research to enhance understanding of molecular basis of PKD and its pathobiology
• Translational research to accelerate development of predictive and therapeutic strategies for PKD
• Clinical research such as small pilot studies
• Epidemiology/data analysis research to conduct secondary data analyses utilizing existing database resources, or to develop new statistical methodologies or test hypotheses using existing data

The PKD Foundation encourages proposals in the following topic areas:

• Autosomal Recessive PKD (ARPKD)
• ADPKD in children
• The role of cilia signaling in cyst development
• Drug delivery mechanisms
• Epidemiology/ data analysis (e.g., using existing datasets)
• Extra-renal manifestations of PKD, including but not limited to congenital hepatic fibrosis, polycystic liver disease and intracranial aneurysms
• Protein dosage or gene therapies
• Innovative approaches to machine learning
• Lifestyle interventions (e.g., in dietary habits)

Funding: up to $120,000 per year for two years

https://pkdcure.org/research/grants/pkd-foundation-research-rfa

Patient-Centered Outcomes and Survivorship Award: Supports high-risk, high-reward studies that span the spectrum of survivorship, health outcomes and comparative effectiveness research, including quality of life, symptom and side effect management, resilience, and co-morbid conditions.

Funding: up to $975K for 3 years.

https://ebrap.org/eBRAP/public/ProgramFY.htm?programFYId=719103

https://ebrap.org/eBRAP/public/Program.htm

Clinical Trial Award: Supports clinical trials with the potential to significantly impact the prevention, treatment or management of symptoms, diseases, or conditions associated with or resulting from military-related toxic exposures

Funding: up to $4.5M for 4 years

Investigator-Initiated Research Award:

Supports studies that will make an important contribution to research and/or patient care for diseases or conditions associated with military related toxic exposures.

Funding: up to $800K for 3 years.

Translational Research Award:

Supports translational research that will accelerate the movement of promising ideas in military-related toxic exposures research into clinical applications, including health care products, interventions, technologies and/or clinical practice guidelines. Translational research should integrate basic science and clinical observations.

Funding: up to $1.5M for 3 years

https://cdmrp.health.mil/funding/terp

https://cdmrp.health.mil/funding/default

Applied Research Award: Supports applied research, defined as work that refines concepts and ideas into potential solutions with a view toward evaluating technical feasibility of promising new knowledge products, pharmacologic agents, behavioral and rehabilitation interventions, diagnostic and therapeutic techniques, clinical guidance and/or emerging approaches and technologies.

Funding: up to $950K for 3 years

Clinical Research Award: Supports clinical research that evaluates orthopaedic-specific factors and interventions; the ORP intends for research supported by this mechanism to generate clinically useful evidence with potential to optimize patient outcomes and inform clinical care or policy.

Funding: up to $3.2M for 4 years

https://ebrap.org/eBRAP/public/Program.htm

https://cdmrp.health.mil/funding/prorp

Idea Development Award (IDA): Promotes new ideas that are ready for further development and have the potential to yield high-impact findings and new avenues of investigation in the rare cancers field.

Funding: up to $490K for 3 years

Resource and Community Development Award (RCDA): Supports the development of research resources and clinical or preclinical datasets that will advance the field of rare cancers research and ultimately improve outcomes for individuals with rare cancers.

Funding: up to $1.12M for 4 years.

https://ebrap.org/eBRAP/public/Program.htm

https://cdmrp.health.mil/funding/rcrp

Applicants may submit a pre-proposal application at any time. Pre-proposals will be reviewed by MJFF within three weeks of submission. Applicants whose pre-proposal is selected for further consideration will be invited to submit a full proposal through one of the four review cycles. 

This program seeks to advance therapeutic development through pre-clinical and/or clinical testing of approaches addressing unmet needs of people with Parkinson’s disease (PD). The program is set up to benefit therapeutics with clear potential to prevent, stop, or delay disease progression or to reduce the burden of daily symptoms.

The Therapeutics Pipeline Program is only open to industry and industry-academia collaborations.

Funding: Award amounts for this program may range from $250,000 for smaller, targeted programs to upwards of $2M for larger, multi-stage preclinical and/or clinical programs

Duration: 1-2 years for pre-clinical programs, 2-3 years for clinical programs

https://www.michaeljfox.org/grant/parkinsons-disease-therapeutics-pipeline-program?em_cid=mc-a1bHq00000AbgaK

Grants to scientists and research professionals in areas including the origins and diagnosis of feline diseases, development of effective treatments, and the identification of disease prevention strategies.

Funding: up to $50,000 over two years.

https://everycat.org/the-latest/grants/open-grant-rfps

Mentored Clinical Research Award: Supports clinical research (e.g., research conducted with human subjects, samples, or data of human origin) by a clinician in training under an established mentor. Funding: up to $75K for 1.5 years.

https://ebrap.org/eBRAP/public/ProgramFY.htm?programFYId=719107

https://ebrap.org/eBRAP/public/Program.htm

An annual award worth €200,000, recognising researchers whose scientific discoveries have had a major impact on the care of patients with cancer.  The Gustave Roussy Prize is awarded each year to a prominent figure in oncology research whose scientific breakthroughs in the fields of cancer diagnosis, treatment, or prevention have significantly improved patient care or led to a better understanding of the disease.  The prize highlights innovation and scientific commitment that led to tangible, lasting benefits for patients, in perfect alignment with Gustave Roussy’s mission: to cure more patients, more effectively and more sustainably. It is endowed with €200,000: €100,000 for the laureate’s free use, and €100,000 to support an innovative research project in oncology.  The Prize is open to researchers of all nationalities. An independent jury of international experts selects the laureate solely on scientific excellence and clinical impact, regardless of discipline or institution.

https://www.gustaveroussy.fr/en/gustave-roussy-prize

The Program will support two investigator-initiated research projects aimed at advancing the biological understanding of the MAST genes and/or accelerating the discovery or development of therapeutic approaches.  Proposed projects must be directly relevant to the biology and clinical manifestations of MAST1, MAST2, MAST3, and/or MAST4 related neurodevelopmental disorders, and must align with at least one of the priority areas below:

1. Disease mechanisms and variant-level biology – Studies that advance understanding of how pathogenic or likely pathogenic variants in MAST1-4 alter protein expression, kinase activity, downstream signaling, or neuronal phenotypes…
2. Therapeutic approaches – Exploratory or proof-of-concept studies aimed at therapeutic discovery and target validation for MAST1 and MAST3 related disorders…
3. Multi-Investigator and Interdisciplinary Collaboration

Funding: $50,000 over 12 months.

https://orphandiseasecenter.squarespace.com/grants/mastgenesloi

In 2026, grants are available in the following areas:

• In-vitro models and assays to identify novel therapies for neuroinflammatory diseases.  To develop predictive in-vitro models aimed at identifying and optimizing novel small molecule medicines for human neuroinflammatory diseases. One grant of up to 500K EUR over 2 years.
• Artificial intelligence in cell culture media and process development. Proposals for robust, host-agnostic, and easy to parameterize models, that enable us to more quickly develop fit-for-purpose solutions for the optimization of bioprocesses for a broad base of host organisms. One grant of up to 150K EUR/year for up to 3 years.
• Innovative approaches to economical remediation of contaminated high volume materials.  Proposals dedicated to the remediation of high-volume, low-contaminated soil and water, with a specific focus on chloro-organic pollutants and particularly those contaminated with hexachlorocyclohexane (HCH).  One grant of up to 150K EUR/year for up to 2 years.
• Condensate-based high-sensitivity cell-free screening assays for the modulation of protein-protein interactions.  One grant of up to 100K EUR/year for up to 3 years.
• Advancing molecule synthesis and discovery – up to 3 grants each comprising a 1-year full Synthia® Retrosynthesis Software license, training, and extensive interaction with our scientists.

www.merckgroup.com/en/research/open-innovation/research-grants.html

Aims to strengthen cooperative research projects that deliberately connect insights from research into common ND’s or age-related processes with NCL research, with a focus on opening new therapeutic avenues that might benefit both conditions.
Funding: €200K
https://www.ncl-stiftung.de/english/what-we-do/

Neurofibromatosis Research Academy – Leadership Award: Supports visionary, established neurofibromatosis investigators with documented history of neurofibromatosis funding, publications, strong mentorship and commitment to leadership to serve as Director and Deputy Director of the Neurofibromatosis Research Academy.

Proposal must address the strategic goal to increase capacity and multi-disciplinary research through support and development of vital resources and the next generation of NF cancer researchers to improve patient care.

Funding: $2.4M up to 4 years.

https://cdmrp.health.mil/funding/nfrp

https://ebrap.org/eBRAP/public/Program.htm

The Foundation will distribute 2 awards every other year to outstanding young scientists dedicated to basic and translational pancreatic cancer research.  The topic of the requested grant applications will be for innovative translational pancreatic cancer research that focuses on bench to bedside advances.  The grant mechanism supports different types of basic and translational projects including pilot and feasibility studies, self-contained research projects, development of new research methodology and development of new research technology. This grant does not support solely clinical research.

Funding: $250,000 over two years.

https://www.aacr.org/grants/victorias-secret-global-fund-career-development-award-pelotonia-aacr/

https://www.rlfcrf.org/funding-opportunities/research-grant

The NPF Milestones to a Cure program invites investigators to identify pivotal scientific questions that must be answered on the path to achieving a cure for psoriatic disease. Psoriatic disease presents as a complex set of immune-mediated conditions that will require a deep understanding of therapeutic targets, interrelatedness to other diseases, and clinical practices associated with maximizing the likelihood that patients can achieve durable disease remission.  This program challenges researchers to consider one or more psoriatic disease conditions and think boldly and creatively about what will need to be known (mechanistically, clinically, translationally) to eventually declare psoriatic disease cured. By supporting especially innovative, high impact approaches, Milestones to a Cure aims to highlight critical research questions and accelerate progress toward the discoveries that will enable cures for psoriatic disease.

Funding: up to $500,000 over two years.

https://www.psoriasis.org/milestones-to-a-cure-rfp/

The EFSD/Lilly Programme will accept applications within any area of basic or clinical diabetes research.

Funding: up to Euro 100K for duration of one year or longer, depending upon the needs of the project and as justified in the application.

www.europeandiabetesfoundation.org/programmes/current-funding-opportunities

The Wings for Life Spinal Cord Research Foundation is a privately funded research charity organisation with the exclusive aim to promote basic and clinical research related to spinal cord injury with the perspective to improve outcomes.

Basic research projects may address the following aspects of traumatic spinal cord injury

• nerve regeneration/plasticity
• neuronal and glial protection
• functional deficits induced by lesions
• preferentially in mammalian models
• preferentially on mechanisms present/validated in humans

Clinical research projects may address

• spinal cord injury management
• other areas related to traumatic spinal cord injury essential to the propagation of neurological and functional recovery

A preference is given to research projects, which have…

• a perspective of translation from the laboratory to the clinical setting
• the potential to provide real benefits to spinal cord injury patients
• a focus on chronic spinal cord injury, in case applicable

Funding mechanisms:

• Individual Grants: intended only to cover the salary of the applicant
• Project Research Grants:  intended to sustain a full research project. Funding: up to 130,000 € per year for up to 3 years. all inclusive. Indirect costs (overhead costs) are limited to 10% of direct costs
• [To be issued] AI Project Grant, From basic to clinical research: intended to sustain the costs of a larger project grant supplemented with in-kind support from Microsoft in Azure Credits.  Funding: up to 300.000 € per year for up to 3 years. Indirect costs (overhead costs) are limited to 10% of direct costs.  Additionally, Azure Credits up to the amount of 300.000 € per year can be requested.

https://www.wingsforlife.com/uk/research/application/#format-3

The program aim is to foster outstanding and innovative scientific research – basic, translational, and clinical – by bringing together international teams of researchers with complementary expertise and resources to work together on a common thematic problem. The proposals should aim to generate new knowledge with the potential to advance the diagnosis, prevention, and treatment of cardiovascular and/or neurovascular disease. Early career investigators play a vital role in these networks, which provide an excellent context for training and career development in cardiovascular and neurovascular research.

Leducq networks (3-6 institutional members) should demonstrate the added value of international collaboration for their research program.

Funding: $9,500,000 over five years.  In the 2026-27 cycle, the Foundation will award four INE grants.

https://www.fondationleducq.org/international-networks-of-excellence-how-to-apply/how-to-apply/

https://www.fondationleducq.org/wp-content/uploads/2025/07/Program-Description-2026.pdf

Concept Award (CA): Supports the exploration of highly innovative new concepts or untested theories that address an important problem relevant to reconstructive transplantation.

Funding: up to $200K for 18 months

https://ebrap.org/eBRAP/public/Program.htm

https://cdmrp.health.mil/funding/rtrp

These awards will help pioneer and accelerate novel drug development for the treatment of Parkinson’s, providing researchers the opportunity to generate the essential data and help bridge the gaps needed to get their projects/compounds ready to enter full scale drug discovery with an industry partner or the Parkinson’s Virtual Biotech.

Looking for projects that will have a clear focus on translational drug development to make a difference to those affected by Parkinson’s.

Funding: There is no minimum award amount and the maximum award amount is £150,000.

For projects involving in vivo work, an award amount of up to £200,000 will be considered.

Lead PI must be UK based

https://www.parkinsons.org.uk/research/drug-accelerator-awards

Intended to fund research projects in breast and gynecologic cancers and to invest in the next generation of female early-stage scientists domestically and globally. The aim of this award is to foster innovation in the understanding, prevention, interception, early detection, diagnosis, and treatment of breast and gynecologic cancers with the goal of eliminating cancer health disparities and improving patient outcomes. The research proposed for funding may be in basic, translational, clinical, or population sciences. Proposals focused on research into the causes of cancer health disparities and approaches to achieve equity in outcomes are especially encouraged.

At the start of the grant term (December 1, 2026) applicants must have started their first independent faculty position within the past 6 years.

Funding: $206,000 over two years.

https://www.aacr.org/wp-content/uploads/2026/07/2026-VS-CDA-Program-Guidelines_Final.pdf

The Lalji Family ALS Award is accepting nominations for individual or team of investigators who have made significant progress impacting the repair and regeneration of neuronal degeneration that may be applied in ALS. Examples include but are not limited to:

• Identification of key modulators of axonal, glial, and neuronal health and degeneration
• Novel therapies including stem cell therapies to repair and/or regenerate axons, motor neurons or glia
• Modalities to enhance neuroplasticity that lead to repair and regeneration
• A root cause-based protocol or system that leads to reduction of inflammation and improvement of neuronal, glial, and/or axonal function
• Neuro-technologies that restore function or communication and enhance quality of life
• Novel methods to increase and improve endogenous neurogenesis
• Restoring nerve muscle communication

Award: $40,000

www.massgeneral.org/neurology/als/news/lalji-family-award-nominations

The terminal degree or completion of residency must have occurred within ten years prior to the award.

Proposals must focus on research directly related to myotonic dystrophy and may include basic, clinical, or applied research. Eligible research areas include, but are not limited to:

• Pathogenesis of DM
• Molecular mechanisms underlying phenotype differences in DM1, DM2, and congenital DM
• Development of diagnostics or biomarkers
• Studies of disease progression or natural history
• Identification and validation of endpoints for drug development
• Standards of care and care integration, including nursing, social work, and psychology
• Epidemiology, health economics, and patient support services
• Therapeutic development, particularly early-stage projects that could leverage additional funding

Proposals focused on DM2 research are given priority for these awards.

Funding: $190,000 over two years.

https://myotonic.org/research/grants-and-funding/opportunities

https://myotonic.org/wp-content/uploads/MDF_RFA-2027-Early-Career-Grants.pdf

Clinical /Translational Research Award: Supports advanced translational research that will accelerate the movement of promising ideas in DMD research into clinical applications.

Funding: up to $1.9M for 4 years

Idea Development Award: Supports the development of impactful, highrisk/high-reward research that could lead to critical discoveries or major advancements that will accelerate progress in improving outcomes for individuals with DMD in the near term.

Funding: up to $500K for 2 years

https://cdmrp.health.mil/funding/dmdrp

https://ebrap.org/eBRAP/public/Program.htm

4.9 | Cure SMA: Spinal Muscular Atrophy – Basic Research

Investigates the causes and biology of SMA, revealing new, more effective ways of treating the disease

Funding: up to $150,000 over 2 years.

The 5-year historical acceptance rate for research proposals to Cure SMA is 28% with an average of 7 grants awarded per year.

www.curesma.org/funding-opportunities/#basic-research-funding-opportunities

www.curesma.org/wp-content/uploads/2026/06/2026-Basic-Research-RFP.pdf

Aiming at supporting fundamental, translational and clinical research programs related to research on intellectual deficiencies of genetic origin
exclusively dedicated to Trisomy 21 research.
Pilot or exploratory grants
For early stage research projects built on preliminary data or small projects that complement larger primary projects.
Funding: 50K EUR for 2 years
Advanced grants
For larger breakthrough projects with substantial preliminary data.
Funding: 80K EUR for 2 years
https://www.research.fondationlejeune.org/call-for-projets/

World-leading innovation grant that supports early-career scientists and physicians to launch their professional journeys in pain research within member countries of the European Pain Federation EFIC®. Directly target clinical and human experimental pain research, including innovative educational initiatives that improve pain diagnosis and treatment.
Funding: max €50K for pup to 2 years
https://www.grunenthal.com/en/world-free-of-pain/initiatives/e-g-g

These grants are awarded to seasoned researchers seeking to make consequential translational discoveries that will drastically alter clinical care for pregnant people and babies, whether through evidence-based prevention, diagnosis, or intervention.

The proposed research should focus on one of these priority topic areas:

1. Spontaneous preterm birth.
2. Cardiovascular health conditions developed during pregnancy or exacerbated during pregnancy

Funding: $200,000 over two years inclusive of 10% indirect costs

https://www.marchofdimes.org/our-work/research/grants-awards/discovery-research-grants

Neurofibromatosis Research Academy – Scholar Award: supports early-career investigators (Scholars) joining the Neurofibromatosis Research Academy to pursue a research project that may include basic, translational, and/or clinical research under the leadership of the NFRA Director and Deputy Director.

Funding: up to $1.2M for 4 years.

Exploration-Hypothesis Development Award: Supports the initial exploration of innovative, high-risk, high-gain, and potentially groundbreaking concepts in NF research

Funding: up to $160K for 2 years.

Investigator-Initiated Research Award: Supports highly rigorous, high-impact research projects that have the potential to make an important contribution to neurofibromatosis research and/or patient care.

Funding: up to $920K for 3 years.

Synergistic Idea Award: Supports new ideas that represent synergistic approaches to NF research involving two or three PIs.

Investigators are expected to demonstrate the synergistic components (i.e., leveraging disciplines, expertise, or critical resources) that will significantly advance the project such that the research outcomes will be realized rapidly and efficiently and could not otherwise be accomplished through the independent efforts of a single investigator.

Funding: up to $3.2M for 3 years.

https://cdmrp.health.mil/funding/nfrp

https://ebrap.org/eBRAP/public/Program.htm

A joint effort to stimulate and develop creative, paradigm-shifting ideas in invasive lobular carcinoma (ILC) that have the potential to advance knowledge of lobular breast cancer detection, diagnosis, pathology, treatment, recurrence prevention, or surveillance.
Funding: $50K for 1 year
https://www.aacr.org/grants/aacr-lbca-invasive-lobular-carcinoma-research-challenge-grants/

Drug Development RFP

The Drug Development RFP supports investigational new drug (IND)-enabling studies (or the international equivalent) and early-phase clinical trials that test promising pharmacological interventions and devices for Alzheimer’s disease (AD) and related dementias. This funding opportunity concentrates on diverse drug mechanisms and modes of action related to the biology of aging and other emerging therapeutic areas for dementia.

Funding: Up to $5,000,000 based on stage and scope of research. No overhead.
Neuroimaging and CSF Biomarker RFP

The aim of this RFP is to further develop and validate established biomarkers for which there is a clear clinical need in Alzheimer’s disease and related dementias. This RFP prioritizes biomarkers with a defined context of use, a clear advantage over other relevant biomarkers, and a path to commercialization and/or clinical use.

Specifically, this RFP focuses on:

• Developing novel PET ligands for clinical trials
• Supporting novel CSF biomarkers
• Validating innovative MRI approaches in larger cohorts
• Developing novel measures of functional activity such as EEG

Funding: Up to $600,000 based on stage and scope of research. No overhead.

Prevention RFP
to support precision prevention studies, combination therapy studies, and comparative effectiveness research that probe whether the use or choice of interventions may reduce the risk of Alzheimer’s disease or other dementias. Studies that are not in humans will not be considered.
Funding: up to $5,000,000 for clinical trials based on stage and scope of research. No overhead.

https://www.alzdiscovery.org/research-and-grants/funding-opportunities

Academy of Kidney Cancer Investigators – Early-Career Scholar Award: Supports impactful kidney cancer research; and integrates new Early-Career Scholars (ECS) into a virtual academy providing intensive mentoring, national networking, research collaborations, and a peer group for early-career kidney cancer investigators

Funding: up to $1.2M for 4 years

Idea Development Award: Supports the development of innovative, high-impact ideas that advance the understanding of kidney cancer and ultimately lead to improved patient outcomes.

Funding: up to $1.2M for 3 years

https://ebrap.org/eBRAP/public/Program.htm

https://cdmrp.health.mil/funding/kcrp

Clinical Trial Award: Supports rapid implementation of clinical trials with the potential to significantly impact ovarian cancer.  • Proposed projects may range from small, proof-of concept trials through large-scale, definitive trials, including early-phase or pilot clinical trials (phase 0, 1 or 1/2).

Funding: up to $2.8M for 4 years

Ovarian Cancer Academy – Early-Career Investigator Award: Supports the addition of new early career investigators to the unique, interactive, virtual academy that provides intensive mentoring, national networking, collaborations and a peer group for junior faculty.

Funding: up to $1.125M for 4 years

Ovarian Cancer Clinical Trial Academy – Early Career Investigator Award:  Supports the addition of new ECIs to the unique, interactive, virtual Clinical Trial Academy that provides intensive mentoring, national networking, collaborations and a peer group for junior faculty.

Funding: up to $1.4M for 4 years

https://ebrap.org/eBRAP/public/Program.htm

https://ebrap.org/eBRAP/public/ProgramFY.htm?programFYId=711101

Focused Pilot Award: Supports the exploration and development of impactful and innovative concepts under a patient centered focus area that could ultimately lead to major advancements that will have a profound effect on patients’ overall quality of life.

Funding: up to $300K for 2 years

https://ebrap.org/eBRAP/public/Program.htm

https://ebrap.org/eBRAP/public/ProgramFY.htm?programFYId=707102

Concept Award (CA): Supports highly innovative, untested, potentially groundbreaking novel concepts in rare cancers.

Funding: up to $140K for 2 years

https://ebrap.org/eBRAP/public/Program.htm

https://cdmrp.health.mil/funding/rcrp

The nominee should have demonstrated academic excellence and achievements in the field of translational cancer research, which we define as a fundamental research discovery that has the potential for future clinical development for the benefit of cancer patients. Nominees may be working on research which has achieved proven clinical applications, or which has not yet done so but shows significant promise in this area.

Nominees must also meet the following criteria:

• Have no more than 15 years post-doctoral experience (or equivalent degree)
• Have spent at least the last five years working in Europe
• Presently be employed in a European institution

Self-nominations and nominations for EACR Board members cannot be accepted.

https://eacr.org/pezcoller-foundation-awards/translational-cancer-researcher-award

The purpose of this Request for Information (RFI) is to solicit ideas on NIH-wide challenges and opportunities from the public that may be of interest to the NIH Common Fund.

Background:  The Common Fund supports bold scientific programs that catalyze discovery across all biomedical and behavioral research. These programs bring together investigators and multiple NIH Institutes, Centers and Offices (ICOs) to collaborate on innovative research. Common Fund programs are expected to address high priority challenges for NIH as a whole and make a broader impact on the scientific community. Many Common Fund programs are designed to produce specific deliverables, such as broadly useful datasets, tools, technologies, research methods, or fundamental scientific paradigms. These deliverables are expected to have exceptional impact on the way science is conducted, our understanding of human physiology or disease, or our ability to support human health.

All Common Fund investments share the following criteria:

• Transformative – strong potential for exceptionally high and broadly applicable impact in biomedical/behavioral research
• Catalytic – time-limited investments of 10 years or less, designed to capitalize on new scientific knowledge or breakthroughs to accelerate and enable subsequent research
• Goal-driven – include defined goals to develop specific deliverables (such as new knowledge, data sets, resources, methods, or technologies)
• Synergistic – advance the missions of multiple NIH Institutes, Centers, and Offices (ICOs), leverage expertise from multiple ICOs, and accelerate research relevant to multiple diseases and conditions
• Novel – pursue innovative solutions to specific scientific challenges important to the NIH mission but that no other entity is likely or able to address

Information requested:  The NIH requests ideas for biomedical and behavioral research challenges and opportunities that may be of interest to the Common Fund. These ideas may inform activities to advance areas of science relevant to these challenges/opportunities, including, but not limited to, scientific workshops, pilot initiatives, and/or future Common Fund programs.

NIH encourages idea submissions that may include, but are not limited to, the following:

• A critical challenge or exciting emerging opportunity in biomedical/behavioral research
• Resources, tools, or knowledge that are needed to address the important challenge or opportunity
• Scientific advancements or other factors that make addressing the important challenge or opportunity particularly timely
• Critical challenges that small labs or research groups face with respect to funding, contracting, or navigating the regulatory landscape
• Priorities from “Advancing NIH’s Mission Through a Unified Strategy” and “Make Our Children Healthy Again Strategy.”

How to submit a response:  All responses must be submitted electronically by 11:59:59 pm (ET), September 19, 2026 using the following website https://rfi.grants.nih.gov/?s=6a22cf1d0957e14467009772.

Responses to this RFI are voluntary and may be submitted anonymously…  This RFI is for information and planning purposes only and is not a solicitation for applications …

https://grants.nih.gov/grants/guide/notice-files/NOT-RM-26-004.html

Through two prestigious Awards of €200,000 each, Fondation ARC rewards top-class researchers whose careers and work have let to major breakthroughs in cancerology.

www.fondation-arc.org/appels-a-projets/55th-fondation-arc-leopold-griffuel-awards

Melanoma Academy Scholar Award: Supports the addition of Scholars to a virtual academy providing intensive mentoring, national networking, collaborations and a peer group for earlycareer melanoma investigators.

Funding: up to $770K for 3 years

Survivorship Research Award: Supports studies addressing melanomaspecific survivorship by supporting a broad range of innovative and impactful research that has the intended outcome of improving the health and well-being of melanoma survivors, their families and/or their care partners

Funding: up to $1.02M for 3 years

https://cdmrp.health.mil/funding/erp

https://cdmrp.health.mil/funding/default

This scheme aims to de-risk early projects to facilitate further drug discovery research, funding, or partnering. We are seeking projects with strong therapeutic potential to deliver patient benefit.  We invite applications for early drug discovery proposals from across all cancer indications and modalities. Some examples of projects we might fund include the following areas:

* deconvolution and validation of novel targets and pathways

* novel therapeutic approaches to validated targets

* development of platforms, assays and screens to identify novel cancer therapeutics or targets

* drug discovery feasibility and progressing more advanced assets

Funding: Up to £250k for up to 18 months.

www.cancerresearchuk.org/funding-for-researchers/our-funding-schemes/therapeutic-catalyst

Funds activities that hold promise of identifying therapies (cures) for paralysis in humans. It has particular focus on placing projects in the research pipeline, that is, enabling scientists to develop the proof concept data necessary to apply for larger NIH grants. The development of effective therapies for chronic injury is a high priority for the organization.  Basic research will be supported if it has clear potential to accelerate progress at the applied end of the continuum and/or if it reflects innovative research or a ‘change of direction’.

Funding: $5K to $75K for 1 year (second year considered, no overhead)

https://mcpf.org/new-investigator-grant-application/

https://mcpf.org/wp-content/uploads/2025/02/MCPF-Research-Guidelines-1.doc

Funds an established, leading PIs pursue a potentially ground-breaking, high-risk project in basic research in ALS.
Funding: 200K CHF (~880,000 NIS) for 2 years (one or two grants will be funded).
https://www.radala-foundation.com/index.html

The Innovator Awards Program enables researchers worldwide to test ideas and collaborate to advance the understanding of IBD. The Foundation encourages applications for high-impact basic and translational research projects that use artificial intelligence (AI), machine learning (ML), big data analytics and various model systems to deepen our understanding of the mechanisms in IBD and accelerate therapeutic discovery in the field.

Funding: Iindividual research projects – up to $150,000;  Collaborative projects involving multiple investigators – up to $300,000. The award period is 12 months.

https://krfoundation.org/grants/funding-opportunities/innovator-awards/

Provide more experienced researchers with seed funding to enable them to collect the preliminary data needed to obtain major, long-term funding from other organizations.

Funding: $100K for one year (No overhead, with possible 1 more year renewal)

https://hdfoundation.org/apply

Resource Development Award: Supports the development of a multiomic atlas generated from well-annotated human BMF samples, with omic data derived from marrow specimens

Funding: up to $1.25M for 2 years

https://ebrap.org/eBRAP/public/Program.htm

https://cdmrp.health.mil/funding/bmfrp

Next Generation Research Grant in ALS: This grant targets early career researchers who are studying disease mechanisms, diagnosis, or treatment of ALS and whose research has potential relevance beyond ALS to other diseases.

Funding: $150,000 for 2 years.

https://www.americanbrainfoundation.org/wp-content/uploads/2026/07/ABF-Next-Gen-RFP_ALS-2yr_2027_rev20260615.pdf

https://proposalcentral.com/GrantOpportunities.asp?GMID=359

Richard Olney Clinician Scientist Grant in ALS: This three-year award supports clinical or preclinical research in ALS. This grant targets early career researchers who are studying disease mechanisms, diagnosis, or treatment of ALS and whose research has potential relevance beyond ALS to other diseases.  This grant is funded by The ALS Association and American Brain Foundation and administered by the American Brain Foundation.

Funding: $240,000 for 3 years

https://www.americanbrainfoundation.org/wp-content/uploads/2026/07/ABF-Next-Gen-RFP_ALS-Olney_2027_rev20260615.pdf

https://proposalcentral.com/GrantOpportunities.asp?GMID=359

supports clinical or preclinical research in peripheral neuropathy. This grant targets early career researchers who are studying disease mechanisms, diagnosis, or treatment of peripheral neuropathy and whose research has potential relevance beyond peripheral neuropathy to other diseases.

This grant provides $75,000 per year for two years, for a total of $150,000.

https://www.americanbrainfoundation.org/wp-content/uploads/2026/07/ABF-Next-Gen-RFP_Peripheral-Neuropathy_2027_rev20260623.pdf

https://proposalcentral.com/GrantOpportunities.asp?GMID=359

This two-year award supports clinical and translational research and training in neuromuscular disease. This grant targets early career researchers who are studying disease mechanisms, diagnosis, or treatment of neuromuscular disease and whose research has potential relevance beyond neuromuscular disease to other conditions. The purpose of this grant is to promote neuromuscular clinical and translational research through fellowships to trainees and to promote the activities of the Neuromuscular Study Group.

This grant provides $75,000 per year for two years, for a total of $150,000

https://www.americanbrainfoundation.org/wp-content/uploads/2026/07/ABF-Next-Gen-RFP_Neuromuscular_NMSG_2027_rev20260702.pdf

https://proposalcentral.com/GrantOpportunities.asp?GMID=359

This programme funds preclinical and clinical research focused on slowing, stopping, or reversing Parkinson’s. We do not fund research which is directed at symptomatic relief.

For preclinical research, we fund grants up to £250,000 (GBP) and prioritise projects that are likely to lead to clinical trials in people with Parkinson’s within 5 years. For clinical research, we fund clinical trials and sub-studies of trials in people with Parkinson’s. The grant amount is flexible, so please contact us ahead of submission if you are thinking of applying for a clinical trial.

The ‘Research Strategy’ provides more information on the types of research we fund, our funding priorities and how we provide funding.

www.cureparkinsons.org.uk/research/for-researchers/apply-for-funding/quarterly-research-grant

Research Strategy: www.cureparkinsons.org.uk/2025/11/an-update-to-our-research-strategy

TRP is designed to accelerate the progression of promising scientific discoveries toward clinical application in blood cancers. The TRP supports projects with a clear path to clinical impact. Early-stage or discovery-focused research may be better suited for our Discovery Grant Program (DGP), and applicants with such projects are encouraged to apply through that mechanism.

For the 2027 grant cycle, TRP applications must demonstrate translational readiness. The following criteria apply:

• Small molecule therapies: Applications must include in vivo proof of concept (POC) in appropriate animal models. In select cases, strong in vitro POC using patient-derived samples may be considered, depending on the mechanism of action.
• Cellular and immunotherapies: In vivo POC is strongly encouraged. However, in vitro POC may be acceptable where it is most appropriate for the therapeutic approach.

Funding:  $750,000 over three years.

https://bloodcancerunited.org/research/grants/translational-research-program-trp

https://llsorg.widen.net/s/zgns9bkdj6/en-trp-guidelines-and-instructions-final

This award recognizes an individual who has made significant research contributions in the search for the cause, prevention of, and cure for ALS. The criteria being used to determine the recipient include recent major scientific impact, long-term scientific impact, and overall impact to ALS.

Funding: $50,000 prize to be used by recipient to continue ALS research.

www.aan.com/research/sheila-essey-award-for-als-research

www.als.org/research/researchers/research-funding-opportunities

Early Investigator Research Award: Supports Parkinson’s disease (PD) research opportunities for investigators in the early stages of their careers; however, the investigator need not have previous Parkinson’s disease research experience.

Funding: up to $1M for 2 years

Investigator-Initiated Research Award: Supports highly rigorous, multidisciplinary, high-impact research projects that have the potential to make an important contribution to PD research.  • Supports the full spectrum of research from basic pre-clinical science through clinical trials.

Funding: up to $2M for 3 years

https://cdmrp.health.mil/funding/prp

https://ebrap.org/eBRAP/public/Program.htm

Provides funding for seed or pilot research projects. The emphasis lies in evaluating feasibility and refining methodologies, shaping the trajectory of potential larger-scale studies.

Funding: Up to $25K for single institution & up to $50K for multi-institution projects.   The funding period is one year (with an opportunity for an additional competitive one year renewal).

https://tango2research.org/research/grants

Designed to support early-stage, pre-development concepts — innovations that have not yet been built or tested, but that hold the potential to transform the landscape of cancer immunotherapy.
The most competitive applicants will propose innovations that address areas where technological advancement can have the greatest impact on cancer immunotherapy and patient outcomes. Such technologies may include, but are not limited to:
Computational systems biology approaches, Advanced cancer (or molecular) profiling technologies, Real-time visualization technologies, Complex multicellular culture systems and Novel therapeutic technologies.
Funding: seed funding of up to $600K over 2-4 years (10% overhead in addition to awarded funds)
https://www.cancerresearch.org/technology-impact-award

NAF funds research through 7 distinct award mechanisms:

-Early Career Investigator Award: a $50,000. 1-year, merit-based, nonrenewable grant designed to support outstanding early-stage scientists who have completed their postdoctoral training within the past 6 years and hold a junior faculty or clinical fellow appointment. This award aims to foster the development of independent research careers by providing seed funding for innovative, high-impact studies in the field of ataxia. Proposals are welcome across the full spectrum of basic, translational, and clinical research, but must have a clear and significant focus on advancing our understanding of the causes, pathogenesis, or treatment of hereditary, sporadic, or acquired ataxias.
-Research Seed Money Award: provides support for new and innovative studies that advance understanding of the cause, pathogenesis, or treatment of hereditary, sporadic, and acquired ataxias. These $50,000, 1-year, merit-based, nonrenewable grants serve as seed funding to assist investigators during the early or pilot phases of research, or as supplemental funding for ongoing innovative projects demonstrating a critical need. It is expected that funded projects will generate preliminary data to support applications for larger grants from other funding sources.
-Pioneer SCA3 Translational Award: s annually granted to independent researchers to support outstanding research proposals that aim to make significant advancements in the development of treatments and/or improvements to patient care for Spinocerebellar Ataxia Type 3 (SCA3). This 1-year, merit-based, nonrenewable grant provides $100,000 in direct research funding. Proposals must have a predominant focus on SCA3 preclinical, translational, or clinical research.
-Michael Lundquist Grant to Advance MSA-C Research:  a $50,000, 1-year, merit-based, nonrenewable grant awarded annually to independent researchers for outstanding proposals that aim to make meaningful advancements in the treatment and care of individuals affected by multiple system atrophy, cerebellar subtype (MSA-C). While proposals may include aspects relevant to other forms of ataxia, the primary focus must be on preclinical, translational, or clinical research directly related to MSA-C.

Researcher Resources

Supports Bavarian state and church-affiliated universities as well as universities of applied sciences (UAS) in establishing international research collaborations and preparing joint research funding proposals.

The funding enables researchers to build new international partnerships and prepare joint third-party funding proposals. Funding is exclusively provided for meetings between Bavarian researchers and their specific partner institutions that serve the targeted initiation or deepening of joint cooperation. The programme therefore focuses on institutionally anchored research partnerships.

Funding: up to EUR 10,000 per project

https://www.bayfor.org/en/about-us/mission/initial-funding-programme-bayintan.html

Process Development Grant:  provides up to $100K to support innovative processes, technologies, tools, and operational models that advance the safe, available, and effective delivery of transfusion medicine and biotherapies. The grant is intended to help improve operational performance, efficiency, quality, safety, accessibility, or decision support.

https://www.aabb.org/foundation/process-development-grant

Early-Career Scientific Research Grant:  provides up to $100K to support investigator-initiated, original research in blood banking, transfusion medicine, and biotherapies. The grant is intended to help early-career investigators advance toward research independence through one- or two-year projects.

An early-career investigators is one that has completed a terminal research degree or medical residency – whichever date is later – within the past 10 years of the grant application deadline and has not yet been awarded a substantial research grant (i.e. NIH R01).

https://www.aabb.org/foundation/early-career-scientific-research-grants-program

We support innovative basic, translational, and clinical research that advances understanding and care for LGS.
Priority Research Areas: LGS biomarkers that predict disease course and/or treatment response / Mortality in LGS / Medical device use in LGS / Disease-modifying therapies targeted to the LGS Secondary Brain Network / Natural history of LGS / Non-seizure issues & quality of life in LGS / Prevention, reversal, and/or stabilization of LGS / Neurodegeneration in LGS / Pediatric-to-adult transition of care in LGS
Funding: up to $75K over 1–2 years.
www.lgsfoundation.org/365-research-grant
www.lgsfoundation.org/wp-content/uploads/2025/11/RFP_-LOI-and-Full-Proposal-Instructions-.docx.pdf

Specific Defect Research Program
Funding collaborative research that explores individual immune system defects and their clinical impact.
Funding: up to $50K over two years.
C.H.I.L.D.R.E.N Global Research Program
Supports research focused on improving outcomes for children with PI worldwide—advancing diagnostics, treatment, and healthcare equity, especially in developing countries.
Funding: up to $50K over two years.
G.E.N.I.E. Program
Advance physician education, foster global collaboration, and promote early diagnosis and better care for Primary Immunodeficiency patients worldwide.
Funding: up to $10K for one year
www.info4pi.org/medical/grants

To provide seed funding for highly innovative research with significant potential to accelerate the mission of the Lustgarten Foundation (Early Detection and Interception, Therapeutic Development, Personalized Medicine).
Preference will be given to proposals addressing understudied and/or poorly understood aspects of pancreatic cancer biology.
Proposals that involve collaborations across groups or that bring new expertise and/or technology into the field will be preferred.
Funding: up to $110K for 1 year
https://lustgarten.org/innovation-collaboration-rfa/

Supports studies that employ CureGN and or NEPTUNE resources to advance clinical and translational research in glomerular disease.  Projects can include, but are not limited to, those that can be used to generate feasibility data to support advancement of promising future studies and projects to develop clinical assays, or protocols, or early phase clinical trials.

Funding: up to $250,000 per project in direct costs only, paid over a 2-year period

https://nephcure.org/about/our-impact/grant-opportunities/

To advance transformational collaborative projects to provide new insights into disease mechanisms or create or implement tools and technologies not previously applied to Huntington’s disease research for the advancement of therapeutics. General areas include but are not limited to: whether modulation of somatic repeat instability is disease modifying, whether and how cellular, biochemical or molecular insights in HD systems are predictive of disease, or how to apply unexplored therapeutics for clinical application (inclusive of biomarkers). Projects that discover disease modifying targets and incorporate novel tools or technologies are encouraged. Projects must justify how results could ultimately connect to therapies.

Funding: $300K-$500K per year for up to a two-year period.

https://hdfoundation.org/apply

 (Abstracts may be submitted at any time until the closing date)

AOI #20 DRIVe Forward

Aims to develop products, capabilities, and technologies to detect threats, improve patient care, including ancillary supplies and resources, as well as novel approaches to develop, clinically validate, and deploy/distribute MCMs rapidly and agnostically.

Especially interested in proposals that aim to address one or more of the following topics:

1. Microbiome-based therapies
2. Resilience to infection
3. Next-generation vaccines
4. Next-generation therapeutic antibodies
5. Artificial blood products
6. Extremely mobile viral diagnostic platforms for use in extremely remote settings
7. Non-pharmacological approaches for enhanced immunity

Funding: up to $750K.

https://drive.hhs.gov/partner.html

https://drive.hhs.gov/files/ezbaa_files/DRIVe_EZ-BAA_Special_Instructions_01.pdf

Frontier Grants facilitate transitions from basic research to attractive prospects for biotech investors

Lundbeck Foundation has now introduced Frontier Grants to support critical activities to advance and consolidate basic research projects, with significant potential, into attractive prospects for investors. The purpose of the grant is to advance mature research projects to become financeable and commercially tangible venture opportunities.

Purpose:

A Frontier Grant (FG) provides financial and interactive support to test and develop the commercial and translational potential of a basic research finding together with the researcher and allowing for mentoring and professional development activity.

Criteria – Who can apply:

Field must be within biomedicine or health sciences, i.e., not limited to brain health.

The research must be affiliated with a Danish non-commercial research institution – international collaboration is allowed.

duration of up to 18 months and a max budget of DKK 5.0 M (with optional 2.5 M and +6 months extension).
https://lundbeckfonden.com/apply-grants/frontier-grants

(Pre-proposals/pre-applications may be submitted at any time throughout the 5-year period from the BAA release date to the BAA closing date)

Research Areas of Interest (please see BAA for more details)

1. Damage Control Resuscitation
2. Prolonged Field Care (PFC)
3. Portable Lab Assays and Diagnostics
4. Force Health Protection and Environmental Medicine
5. Brain Health
6. Immune Response
7. Chronic Pain
8. Automation of Systematic Reviews and Metanalysis
9. Medical Simulation and Training Technologies
10. Human Performance Optimization
11. Canine Medicine and Performance

Most projects are anticipated to have a total cost at or below $1,500,000 (including indirect costs). Projects that have a total cost higher than $1,500,000 (including Indirect costs) with outstanding scientific merit that meet a critical need may be accepted; however the total cost of these projects are not to exceed $5,000,000.00 (including Indirect costs).

Duration: up to 5 years.

https://ebrap.org/eBRAP/public/ProgramFY.htm?programFYId=549113

to advance the current understanding of Malan syndrome and identify disease-modifying treatments.

Funding: up to $30,000 for one year, may be renewed for a second year, based on satisfactory progress.

www.malansyndrome.org/research-grant-program

https://drive.google.com/file/d/1m-RReH2f7jUsmYsXtknPSVORepn_ecdr/view